



2023 CIBMTR Report of Survival Statistics for Blood and Marrow Transplants

July 24, 2024

Contents

Abbreviations	4
Introduction	5
Results	6
References	81

Tables

Table 1 Characteristics of patients \leq 18 years of age receiving autologous transplants for non-Hodgkin lymphoma during July 2011-June 2021	7
Table 2 Characteristics of patients $>$ 18 years of age receiving autologous transplant for non-Hodgkin lymphoma during July 2011-June 2021	8
Table 3 Characteristics of patients \leq 18 years of age receiving autologous transplants for Hodgkin lymphoma during July 2011-June 2021, by remission status	10
Table 4 Characteristics of patients $>$ 18 years of age receiving autologous transplants for Hodgkin lymphoma during July 2011-June 2021, by remission status	11
Table 5 Characteristics of patients \leq 18 years of age receiving autologous transplants for acute myeloid leukemia between July 2011-June 2021, by remission status.....	13
Table 6 Characteristics of patients $>$ 18 years of age receiving autologous transplants for acute myeloid leukemia between July 2011-June 2021, by remission status.....	14
Table 7 Characteristics of patients \leq 18 years of age receiving autologous transplants for acute lymphoblastic leukemia between July 2011-June 2021, by remission status	15
Table 8 Characteristics of patients $>$ 18 years of age receiving autologous transplants for acute lymphoblastic leukemia during July 2011-June 2021, by remission status	16
Table 9 Characteristics of patients receiving autologous transplants for multiple myeloma during July 2011-June 2021.....	17
Table 10 Characteristics of patients receiving autologous transplants for neuroblastoma during July 2011-June 2021.....	18
Table 11 Characteristics of patients receiving autologous transplants for testicular cancer during July 2011-June 2021.....	19
Table 12 Characteristics of patients \leq 18 years of age receiving autologous transplants for central nervous system tumors (except CNS lymphoma and neuroblastoma) during July 2011-June 2021	20
Table 13 Characteristics of patients $>$ 18 years of age receiving autologous transplants for central nervous system tumors (except CNS lymphoma and neuroblastoma) during July 2011-June 2021	21
Table 14 Characteristics of patients receiving HLA-identical sibling transplant for chronic myeloid leukemia during July 2011-June 2021, by disease phase	22

Table 15 Characteristics of patients receiving transplant other than HLA-identical sibling for chronic myeloid leukemia during July 2011-June 2021, by disease phase	24
Table 16 Characteristics of patients ≤ 18 years of age receiving HLA-identical sibling transplant for acute myeloid leukemia between July 2011 and June 2021, by disease status	27
Table 17 Characteristics of patients > 18 years of age receiving HLA-identical sibling transplant for acute myeloid leukemia during July 2011-June 2021, by remission state	29
Table 18 Characteristics of patients ≤ 18 years of age receiving transplant from donors other than HLA-identical sibling for acute myeloid leukemia during July 2011-June 2021, by remission state.....	31
Table 19 Characteristics of patients > 18 years of age receiving transplant from donors other than HLA-identical sibling for acute myeloid leukemia during July 2011-June 2021, by remission state.....	34
Table 20 Characteristics of patients ≤ 18 years of age receiving HLA-identical sibling transplant for acute lymphoblastic leukemia during July 2011-June 2021, by remission state	37
Table 21 Characteristics of patients > 18 years of age receiving HLA-identical sibling transplant for acute lymphoblastic leukemia during July 2011-June 2021, by remission state.....	39
Table 22 Characteristics of patients ≤ 18 years of age receiving transplants from donors other than HLA-identical siblings for acute lymphoblastic leukemia during July 2011-June 2021, by remission state	41
Table 23 Characteristics of patients > 18 years of age receiving transplants from donors other than HLA-identical siblings for acute lymphoblastic leukemia during July 2011-June 2021, by remission state	43
Table 24 Characteristics of patients receiving HLA-identical sibling transplants for myelodysplastic syndrome during July 2011-June 2021, by disease stage	46
Table 25 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for myelodysplastic syndrome during July 2011-June 2021, by disease stage.....	48
Table 26 Characteristics of patients receiving HLA-identical sibling transplants for non-Hodgkin lymphoma during July 2011-June 2021, by disease subtype.....	50
Table 27 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for non-Hodgkin lymphoma during July 2011-June 2021, by disease stage	54
Table 28 Characteristics of patients receiving allogeneic transplants for Hodgkin lymphoma during July 2011-June 2021, by donor type	58
Table 29 Characteristics of patients receiving HLA-identical sibling transplants for multiple myeloma during July 2011-June 2021, by time from DX to HCT	61
Table 30 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for multiple myeloma during July 2011-June 2021, by time from DX to HCT	63
Table 31 Characteristics of patients ≤ 18 years of age receiving allogeneic transplants for severe aplastic anemia during July 2011-June 2021, by donor type.....	65
Table 32 Characteristics of patients > 18 years of age receiving allogeneic transplants for severe aplastic anemia during July 2011-June 2021, by donor type.....	68
Table 33 Characteristics of patients receiving allogeneic transplants for Fanconi anemia during July 2011-June 2021, by donor type	71

Table 34 Characteristics of patients receiving allogeneic transplants for thalassemia between July 2011- June 2021, by donor type	73
Table 35 Characteristics of patients receiving allogeneic transplants for SCID during July 2011-June 2021, by donor type.....	75
Table 36 Characteristics of patients receiving allogeneic transplants for inherited disorders during July 2011-June 2021, by donor type	78

Abbreviations

Abbreviation	Definition
allo	allogeneic
auto	autologous
BCNU	carmustine
BEAM	carmustine (BCNU), etoposide, cytarabine (Ara-C) and melphalan
Bu	Busulfan
Carb	carboplatin
CBV	cyclophosphamide, carmustine (BCNU) and etoposide (VP-16)
CI	confidence interval
CIBMTR	Center for International Blood and Marrow Transplant Research
CNI	calcineurin inhibitor
CNS	central nervous system
CR	complete remission
CR ≥ 2	second or greater complete remission
CR1	first complete remission
CR2	second complete remission
Cy	cyclophosphamide
DX	diagnosis
Etop	etoposide
FCR	fludarabine, cyclophosphamide and rituximab
Flu	fludarabine
GVHD	graft-versus-host disease
Haplo	haploidentical
HCT	hematopoietic cell transplantation
HLA	human leukocyte antigen
Mel	melphalan
MTX	methotrexate
NE	not evaluable
NMA	nonmyeloablative conditioning
PT-Cy	post-transplant cyclophosphamide
RIC	reduced-intensity conditioning
SCID	severe combined immunodeficiency
TBI	total body irradiation
TLI	total lymphoid irradiation
TT	thiotepa
US	United States

Introduction

The following tables describe use and outcome of autologous and allogeneic blood and bone marrow transplants in the more than 350 centers participating in CIBMTR® (Center for International Blood and Marrow Transplant Research®). Prior to 2007, we estimate CIBMTR captured 90% of all unrelated donor transplants performed in the US, 60-90% of related donor allogeneic transplants, and 65-75% of autologous transplants. After 2007, CIBMTR collects data on all allogeneic transplants performed in the US and 80% of autologous transplants.

Table 1-13 (autologous) and Tables 14-36 (allogeneic) show patient characteristics and probabilities of survival ($\pm 95\%$ CIs) post-transplant at 100 days, and at 1, 3 and 5 years. Categorical variables are represented by N (%), continuous variables by median (range). Probabilities were calculated using the Kaplan-Meier estimator. Some groups lack sufficient data for calculation of probabilities beyond 2-3 years. These are indicated by footnotes which give the time of the last censored observation. Outcomes were stratified on disease and disease state pre-transplant. However, it should be remembered that these groups are still heterogeneous with regard to age, prior treatment, chemotherapy-sensitivity and other important prognostic factors. Extrapolating to individual patients or centers may not be appropriate.

The enclosed raw data represent a preliminary review of information registered to CIBMTR. The analysis has not been reviewed or approved by the Advisory or Scientific Committee of CIBMTR.

PLEASE NOTE: The enclosed data are for your own information and may be used in oral, but not written presentations. Unauthorized reproduction is prohibited.

Please contact CIBMTR for information on obtaining written permission to reproduce the enclosed data.

Data source

CIBMTR is research collaboration of the Medical College of Wisconsin and NMDP. CIBMTR collaborates with scientists around the globe to study cellular therapies and cure life-threatening diseases, many of which are rare.

More than 350 medical centers worldwide submit clinical data to CIBMTR about hematopoietic cell transplantation and other cellular therapies, such as chimeric antigen receptor T cells (CAR-Ts). These therapies treat malignant and non-malignant hematologic conditions and some other disorders. By analyzing these data, CIBMTR identifies the best treatments to help people live longer and enjoy better quality of life.

CIBMTR maintains one of the world's largest observational databases of clinical information on HCT and other cellular therapies. Data are collected, stored and shared under terms of the *Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries* and its accompanying consent forms.¹⁻⁵ At the time of treatment, patients consent for their data to be entered into the Research Database and used to support a broad research agenda. Currently, CIBMTR's Research Database includes long-term clinical data from more than 675,000 patients.

The database includes:

- Almost 100% of allogeneic transplants in the US
- More than 85% of autologous transplants in the US
- About 22,000 patients who received other cellular therapies

CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database, awarded by the Health Resources and Services Administration of the US Department of Health and Human Services. As the contract holder, CIBMTR is charged with collecting data on all allogeneic (related and unrelated) hematopoietic cell transplantations performed in the US. All US transplant centers are required to report data to CIBMTR; participation of non-US centers is voluntary.

CIBMTR also maintains a biorepository with tissue samples.⁵ CIBMTR's unique staff of physicians, biostatisticians, research coordinators, data management staff and IT teams conduct both observational research and clinical trials.

Transplant data

CIBMTR collects transplant data on 2 levels: Transplant Essential Data (TED) and Comprehensive Report Form (CRF). CIBMTR collects TED data on all patients. TED data are an internationally accepted standard data set that includes hundreds of details about patients' demographics, disease, treatment, response, side effects, and long-term outcomes. Using a regularly reviewed, weighted algorithm, CIBMTR selects a subset of patients for more detailed CRF data collection.

Approximately 75% of CIBMTR centers provide CRF data; this accounts for more than 25% of cases submitted to CIBMTR annually.

TED and CRF data are collected pre-transplant, 100 days post-transplant, 6 months post-transplant, annually until year 6 post-transplant, and biannually thereafter until death or lost to follow-up.

Data quality

CIBMTR subjects data to a series of automated and manual quality checks. CIBMTR data operations teams work directly with centers to maintain both consistency and quality of data collected. In addition, CIBMTR performs on-site source data audits, and each member center is audited within a 4-year cycle. These validations and verifications produce high-quality data. If a center fails to meet data quality standards, its data are removed (embargoed) from research studies.

Ethics

CIBMTR protects the privacy and human rights of participants.⁶ CIBMTR obeys international laws and ethical guidelines, including the United States Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR). The NMDP Institutional Review Board, which is fully accredited by the Association for the Accreditation of Human Research Protection Programs, reviews CIBMTR's research. Patients and/or guardian(s) give informed consent for research.

Results

Note: The enclosed data are confidential and represent a preliminary review of information submitted to the CIBMTR. The analysis has not been reviewed or approved by the Statistical or Scientific Committees of the CIBMTR. The data may not be published without prior approval of the CIBMTR.